


Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1. (Original) A compound of formula I:



wherein

A is selected from O and S;

X is selected from phenyl optionally substituted with up to 5 substituents each independently selected from halo, C₁-C₄ alkyl and C₁-C₄ alkoxy; thienyl optionally substituted with up to 3 substituents each independently selected from halo and C₁-C₄ alkyl; and C₂-C₈ alkyl, C₂-C₈ alkenyl, C₃-C₈ cycloalkyl and C₄-C₈ cycloalkylalkyl, each of which may be optionally substituted with up to 3 substituents each independently selected from halo, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ alkyl-S(O)_n- where n is 0, 1 or 2, -CF₃, -CN and -CONH₂;

Y is selected from phenyl, naphthyl, dihydrobenzothienyl, benzothiazolyl, benzoisothiazolyl, quinolyl, isoquinolyl, naphthyridyl, thienopyridyl, indanyl, 1,3-benzodioxolyl, benzothienyl, indolyl and benzofuranyl, each of which may be optionally substituted with up to 4 or, where possible, up to 5 substituents each independently selected from halo, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ alkyl-S(O)_n- where n is 0, 1 or 2, nitro, acetyl, -CF₃, -SCF₃ and cyano; and when Y is indolyl it

may be substituted or further substituted by an N-substituent selected from C₁-C₄ alkyl;


Z is selected from OR₃ or F, wherein R₃ is selected from H, C₁-C₆ alkyl and phenyl C₁-C₆ alkyl;

R₁ and R₂ are each independently H or C₁-C₄ alkyl;


or a pharmaceutically acceptable salt thereof

with the proviso that when Y is optionally substituted phenyl or optionally substituted 1,3-benzodioxolyl and Z is OR₃ and X is optionally substituted phenyl then A is S.


2. (Original) A compound as claimed in Claim 1, wherein A is O.
3. (Original) A compound as claimed in Claim 1, wherein A is S.
4. (Currently Amended) A compound as claimed in any one of the ~~preceding~~ Claims 1-3, wherein one of R₁ and R₂ is H.
5. (Currently Amended) A compounds as claimed in any one of the ~~preceding~~ Claims 1-3, wherein one of R₁ and R₂ is H and the other is methyl.
6. (Currently Amended) A compound as claimed in any one of the ~~preceding~~ Claims 1-3, wherein the compound possesses the stereochemistry defined in formula II




7. (Currently Amended) A compound as claimed in ~~any one of~~ Claims 1 ~~to~~ 5, wherein the compound possesses the stereochemistry defined in formula III




8. (Currently Amended) A compound as claimed in ~~any one of~~ Claims 1 ~~to~~ 5, wherein the compound possesses the stereochemistry defined in formula IV




9. (Currently Amended) A compound as claimed in ~~any one of~~ Claims 1 ~~to~~ 5, wherein the compound possesses the stereochemistry defined in formula V




10. (Original) A compound as claimed in Claim 7 or Claim 8, wherein the compound possesses the stereochemistry defined in formula VI




11. (Original) A compound as claimed in Claim 7 or Claim 9, wherein the compound possesses the stereochemistry defined in formula VII



12. (Currently Amended) A compound as claimed in Claim ~~6~~ or claim 9, wherein the compound possesses the stereochemistry defined in formula VIII



13. (Currently Amended) A compound as claimed in Claim ~~6~~ or claim 8, wherein the compound possesses the stereochemistry defined in formula IX



14. (Currently Amended) A compound as claimed in ~~any one of the preceding~~ Claims 1 wherein Z is F.

15. (Currently Amended) A compound as claimed in ~~any one of~~ Claims ~~1 to 13~~ wherein Z is OH.

16. (Currently Amended) A compound as claimed in ~~any one of~~ Claims ~~1 to 13~~ wherein Z is OMe or OCH₂Ph.

17. (Currently Amended) A compound as claimed in ~~any one of the preceding~~ Claims 1, wherein X is unsubstituted phenyl or phenyl which is mono-, di- or tri-substituted with substituents independently selected from halo, C₁-C₄ alkyl and C₁-C₄ alkoxy.

18. (Original) A compound as claimed in Claim 17, wherein X is unsubstituted phenyl or phenyl which is mono-substituted with fluorine.

19. (Currently Amended) A compound as claimed in ~~any one of the preceding~~ Claims 1, wherein Y is phenyl optionally substituted with up to 5 substituents each independently selected from halo, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ alkyl-S(O)_n- where n is 0, 1 or 2, nitro, acetyl, -CF₃, -SCF₃ and cyano.

20. (Original) A compound as claimed in Claim 19, wherein Y is unsubstituted phenyl or phenyl which is mono-substituted with chlorine.

21. (Currently Amended) A compound as claimed in ~~any one of the preceding~~ Claims 1, wherein Y is naphthyl optionally substituted with up to 5 substituents each independently selected from halo, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ alkyl-S(O)_n- where n is 0, 1 or 2, nitro, acetyl, -CF₃, -SCF₃ and cyano.

22. (Original) A compound as claimed in Claim 21, wherein Y is unsubstituted naphthyl or naphthyl which is mono-substituted with fluorine.

23. (Original) A compound as claimed in Claim 21 or 22, wherein the point of attachment of the optionally substituted naphthyl group to the O or S atom is attachment at the 1 position.

24. (Currently Amended) A compound as claimed in ~~any one of the~~ Claims 1-18, wherein Y is benzofuranyl optionally substituted with up to 5 substituents each independently selected from halo, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ alkyl-S(O)_n- where n is 0, 1 or 2, nitro, acetyl, -CF₃, -SCF₃ and cyano.

25. (Original) A compound as claimed in Claim 24, wherein Y is unsubstituted benzofuranyl or benzofuranyl which is mono-substituted with CH₃.

26. (Currently Amended) A compound as claimed in ~~any one of the~~ Claims 1-18, wherein Y is benzothienyl optionally substituted with up to 5 substituents each independently selected from halo, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ alkyl-S(O)_n- where n is 0, 1 or 2, nitro, acetyl, -CF₃, -SCF₃ and cyano.

27. (Original) A compound as claimed in Claim 26, wherein Y is unsubstituted benzothienyl or benzothienyl which is mono-substituted with fluorine.

28. (Currently Amended) A compound as claimed in ~~any one of the~~ Claims 1-18, wherein Y is benzoisothiazolyl optionally substituted with up to 4 substituents each independently selected from halo, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ alkyl-S(O)_n- where n is 0, 1 or 2, nitro, acetyl, -CF₃, -SCF₃ and cyano.

29. (Original) A compound as claimed in any one of Claims 24-28, wherein the point of attachment of the group Y to the O or S atom is attachment at the 7 position.

30. (Original) A compound as claimed in any one of Claims 24-28, wherein the point of attachment of the group Y to the O or S atom is attachment at the 4 position.

31. (Currently Amended) A pharmaceutical composition comprising a compound of formula I or a pharmaceutically acceptable salt thereof, as defined in ~~any one of~~ Claims 1-30, together with a pharmaceutically acceptable diluent or carrier.

32. (Currently Amended) A compound of formula I or a pharmaceutically acceptable salt thereof, as defined in ~~any one of~~ Claims 1-30, for use as a pharmaceutical.

33. (Currently Amended) A compound of formula I or a pharmaceutically acceptable salt thereof, as defined in ~~any one of~~ Claims 1-30, for use as a selective inhibitor of the reuptake of both serotonin and norepinephrine.

34. (Currently Amended) A compound of formula I or a pharmaceutically acceptable salt thereof, as defined in ~~any one of~~ Claims 1-30, for use in the treatment of a disorder associated with serotonin and norepinephrine dysfunction in mammals.

35. (Currently Amended) A compound of formula I or a pharmaceutically acceptable salt thereof, as defined in ~~any one of~~ Claims 1-30, for use in the treatment of a disorder selected from depression, OCD, anxiety, memory loss, urinary incontinence, conduct disorders, ADHD, obesity, alcoholism, smoking cessation, hot flushes/flushes and pain.

36. (Cancelled)

37. (Cancelled)

38. (Cancelled)

39. (Cancelled)

40. (Currently Amended) A method for selectively inhibiting the reuptake of serotonin and norepinephrine in mammals, comprising administering to a patient in need thereof an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof, as defined in ~~any one of~~ Claims 1-30.

41. (Currently Amended) A method for treating disorders associated with serotonin and norepinephrine dysfunction in mammals, comprising administering to a patient in need thereof an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof, as defined in ~~any one of~~ Claims 1-30.

42. (Currently Amended) A method for treating a disorder selected from depression, OCD, anxiety, memory loss, urinary incontinence, conduct disorders, ADHD, obesity, alcoholism, smoking cessation, hot flushes/flushes and pain comprising administering to a patient in need thereof an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof, as defined in ~~any one of~~ Claims 1-30.

43. (Cancelled)

44. (Original) A method as claimed in any one of Claims 40-42, wherein the disorder is pain.